查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1994147

生殖器皰疹治療市場：依分子、治療模式、給藥途徑、適應症、最終用戶和通路分類－2026-2032年全球市場預測

Genital Herpes Treatment Market by Molecule, Therapy Model, Route Of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，生殖器皰疹治療市場價值將達到 22.8 億美元，到 2026 年將成長至 24 億美元，到 2032 年將達到 32.2 億美元，複合年成長率為 5.05%。

主要市場統計數據
基準年 2025 22.8億美元
預計年份：2026年 24億美元
預測年份 2032 32.2億美元
複合年成長率 (%) 5.05%

本文概述了目前生殖器皰疹治療的臨床路徑、診斷技術的進步以及以患者為中心的護理方法，這些特點構成了現代生殖器皰疹治療的模式。

生殖器皰疹仍然是臨床和公共衛生領域的一大挑戰，其管理需要整合抗病毒治療、診斷、病患教育和醫療保健系統協調。臨床診療路徑取決於急性症狀的發展、無症狀病毒排放以及抑制性或預防性抗病毒藥物的策略性使用，以降低復發和感染的風險。近年來，治療模式已逐漸演變為以患者為中心的治療方法，力求在療效、耐受性、用藥依從性和成本效益之間取得平衡。

探索推動生殖器皰疹診斷、取得和臨床決策新時代的技術、供應鏈和治療方法創新。

生殖器皰疹的治療格局正在經歷一系列重大變革，這些變革正在重塑臨床實踐和商業性趨勢。第一波變革來自技術層面。分子診斷技術的進步和遠端醫療的普及使得早期診斷和更持續的後續觀察成為可能，進而影響抗病毒藥物的處方和更新方式及時間。同時，數位健康平台正在改變患者參與、藥物依從性監測和處方藥分發的方式，從而在患者和醫療服務提供者之間建立新的聯繫點。

本分析探討了近期關稅政策如何促使抗病毒療法供應鏈進行重組、採購系統進行調整以及對製造業韌性進行投資。

美國近期推出的關稅措施為參與抗病毒療法及其相關成分的生產、進口和分銷的相關人員帶來了新的考量。關稅帶來的成本壓力波及全球供應鏈，並可能影響活性成分、成品及包裝材料的成本結構。為此，製造商和合約供應商正在重新審視籌資策略，一些企業加快了近岸外包的步伐，其他企業則致力於供應商多元化，以降低單一來源風險。

將分子、治療模型、分銷、給藥途徑、最終用戶和適應症細分轉化為清晰的策略觀點，供臨床和商業決策者參考。

一套精細的市場區隔框架從分子層面的差異入手，有助於明確臨床需求、分銷動態和商業性重點的交會點。本報告分析了阿昔洛韋、泛昔洛韋和伐昔洛韋的市場，並列出了每種已上市藥物的品牌藥和非專利藥。這些分子差異指導臨床醫師在選擇用於間歇性治療和抑制性治療的藥物時，會考慮藥物動力學、依從性和指南因素，從而指導處方模式和定價策略。

本文旨在闡明區域法規結構、製造能力、分銷管道和文化因素如何影響世界各地市場的准入和臨床實踐。

區域趨勢影響著治療方法的開發、監管、採購和交付，美洲、歐洲、中東、非洲和亞太地區的實際情況各不相同。在美洲，私營部門的創新、遠端醫療的普及以及零售和線上藥局管道的蓬勃發展，正在推動數位化醫療模式的快速傳播。同時，與支付方的合約以及處方藥清單的管理仍然影響著處方選擇和治療的連續性。

了解製造商、經銷商、診斷服務提供者和臨床服務網路之間的競爭定位、夥伴關係策略和差異化因素。

生殖器皰疹治療領域的競爭動態反映了成熟的小分子抗病毒藥物、不斷擴大的學名藥供應基礎以及新興的臨床和商業服務供應商之間的平衡。品牌藥生產商傳統上透過與醫生的關係、臨床數據和品牌教育來確立其臨床地位，而學名藥生產商則利用成本效益和廣泛的分銷網路來擴大其市場覆蓋範圍。契約製造生產商和專業的供應鏈合作夥伴在支持靈活的生產計劃和確保符合跨市場監管品質標準方面發揮著至關重要的作用。

製造商、支付方和醫療保健提供者面臨的可操作的策略挑戰，旨在加強供應鏈韌性、整合診斷以及擴大以患者為中心的就醫途徑。

產業領導者應採取協作策略，整合供應鏈韌性、臨床證據的建立以及以病人為中心的配送模式。首先，他們應優先考慮供應商多元化和發展靈活的生產能力，以減少對單一供應商的依賴，並應對政策帶來的快速變化的需求和成本壓力。同時，投資國內或區域生產能力可以降低跨境關稅和運輸風險，並縮短補貨前置作業時間。

為了確保獲得可靠的見解，我們描述了一種綜合的混合方法研究途徑，該方法結合了臨床文獻回顧、監管分析、相關人員訪談和供應鏈檢驗。

本分析所依據的研究採用了一種多方法途徑，整合了同行評審的臨床文獻、監管文件、供應鏈資訊以及相關人員訪談。臨床見解來自近期臨床試驗、指南更新以及醫學文獻中記錄的實踐模式評估，而監管和採購方面的觀察則是基於公開記錄和政策分析。供應鏈和製造趨勢反映了對行業營運經理和契約製造專家的訪談，並輔以關於貿易和關稅影響的二手文獻。

本研究整合了診斷技術進步、通路演變和製劑創新等面向的策略意義，以期持續改善生殖器皰疹的治療。

簡而言之，生殖器皰疹的臨床和商業性管理正因診斷技術的進步、分銷管道的創新以及人們對長期控制和預防期望的轉變而發生重塑。相關人員必須權衡現有口服抗病毒藥物的持續作用與不斷變化的用藥途徑、日益普及的學名藥以及人們對能夠變革長期護理模式的製劑和預防策略的重新關注。鑑於影響成本結構和採購行為的政策變化，供應鏈韌性和策略採購變得日益重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 生殖器皰疹治療市場：依分子類型分類

  • 阿昔洛韋
    • 品牌商品
    • 非專利的
  • 泛昔洛韋
    • 品牌商品
    • 非專利的
  • 伐昔洛韋
    • 品牌商品
    • 非專利的

第9章：生殖器皰疹治療市場（依治療模式分類）

  • 癲癇治療
  • 預防性治療
  • 抑制療法

第10章 生殖器皰疹治療市場：依給藥途徑分類

  • 靜脈注射
    • 居家靜脈輸液
    • 醫院管理
  • 口服
    • 膠囊
    • 液體
    • 藥片
  • 外用
    • 奶油
    • 軟膏

第11章 生殖器皰疹治療市場：依適應症分類

  • 無症狀性排放
  • 初始感染
    • 成人
    • 兒童
  • 復發期
    • 首次復發
    • 多次復發

第12章 生殖器皰疹治療市場：依最終使用者分類

  • 居家醫療環境
    • 由護理師管理
    • 自我管理
  • 醫院
    • 私人的
    • 民眾
  • 專科診所
    • 皮膚科診所
    • 性行為感染傳染病（STD）診所

第13章 生殖器皰疹治療市場：依通路分類

  • 醫院藥房
    • 私立醫院的藥房
    • 公立醫院藥房
  • 網路藥房
    • 廠商直銷
    • 第三方電子商務零售商
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房

第14章 生殖器皰疹治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 生殖器皰疹治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 生殖器皰疹治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國生殖器皰疹治療市場

第18章：中國生殖器皰疹治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Abcam PLC
  • Aurobindo Pharma Limited
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Cipla Limited
  • DiaSorin SpA
  • Dr. Reddy's Laboratories Ltd
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals plc
  • Hologic, Inc.
  • Luminex Corporation-A DiaSorin Company
  • Lupin Limited
  • Merck KGaA
  • Meridian Bioscience, Inc. by SD Biosensor and SJL Partners
  • Norgen Biotek Corporation
  • OneCare Media, LLC
  • Qiagen NV
  • Quidel Corporation
  • Rapid STD Testing by RSC Health, PA
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd
  • Teco Diagnostics
  • Teva Pharmaceutical Industries Ltd
  • Thermo Fisher Scientific, Inc.
  • Viatris Inc
Product Code: MRR-1A1A064C0410

The Genital Herpes Treatment Market was valued at USD 2.28 billion in 2025 and is projected to grow to USD 2.40 billion in 2026, with a CAGR of 5.05%, reaching USD 3.22 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.28 billion
Estimated Year [2026] USD 2.40 billion
Forecast Year [2032] USD 3.22 billion
CAGR (%) 5.05%

Contextualizing current clinical pathways, diagnostics advances, and patient-centered care approaches that define contemporary genital herpes treatment environments

Genital herpes remains a persistent clinical and public health challenge, and its management integrates antiviral pharmacotherapy, diagnostics, patient education, and health system coordination. Clinical pathways are shaped by acute symptomatic episodes, asymptomatic viral shedding, and the strategic use of suppressive or prophylactic antivirals to reduce recurrence and transmission risk. Over recent years, care paradigms have evolved to emphasize patient-centered approaches that balance efficacy, tolerability, adherence, and cost considerations.

Diagnostics have advanced from syndromic assessment toward nucleic acid amplification testing and point-of-care molecular options, enabling more precise therapy targeting and counseling. At the same time, telehealth and digital adherence tools have emerged as complementary means to support follow-up, counseling, and repeat prescriptions, improving continuity of care for populations that face stigma or limited clinic access. Clinicians increasingly integrate psychosocial support and sexual health counseling alongside antiviral prescribing to address quality-of-life impacts.

From the therapeutics perspective, established oral antivirals occupy the core of outpatient management, while topical and intravenous routes retain specific niche roles in severe or atypical presentations. Preventive strategies and vaccine research continue to generate scientific interest, even as clinical application remains nascent. As a result, stakeholders across manufacturing, distribution, clinical practice, and policy must adapt to a landscape where clinical best practices, technology-enabled delivery models, and regulatory oversight converge to shape patient outcomes and access.

Examining technological, supply chain, and therapeutic innovations that are driving a new era of diagnostics, access, and clinical decision-making in genital herpes care

The treatment landscape for genital herpes is undergoing a series of substantive shifts that are reshaping clinical practice and commercial dynamics. The first wave of change is technological: improvements in molecular diagnostics and the proliferation of telemedicine are enabling earlier diagnosis and more consistent follow-up, which in turn affects how and when antivirals are prescribed and renewed. Concurrently, digital health platforms are altering patient engagement, adherence monitoring, and the distribution of prescription medicines, creating new points of contact between patients and providers.

Another major transition is the consolidation of oral antiviral therapy as the backbone of outpatient management, coupled with an expanding generic footprint that alters pricing and access dynamics. Alongside this, there is growing interest in long-acting formulations and vaccine candidates that, if successful, would recalibrate prevention and long-term management strategies. Supply chain resilience has become a strategic priority, with manufacturers and distributors reevaluating sourcing, inventory management, and contract manufacturing relationships to reduce vulnerability to disruptions.

Finally, payer and regulatory attention to value, real-world effectiveness, and adherence is increasing. Health systems are emphasizing outcomes that extend beyond symptom control to include transmission risk reduction and patient-reported outcomes. Together, these shifts underscore a landscape in which innovation in diagnostics, delivery models, and therapeutic modalities is interacting with commercial and regulatory pressures to create both challenges and opportunities for stakeholders.

Analyzing how recent tariff policies are prompting supply chain realignment, procurement adaptations, and investment in manufacturing resilience for antiviral therapies

Recent tariff measures in the United States have introduced a new set of considerations for stakeholders involved in the production, importation, and distribution of antiviral therapies and related components. Tariff-related cost pressures can propagate through global supply chains, affecting the cost structure of active pharmaceutical ingredients, finished dosage forms, and packaging materials. In response, manufacturers and contract suppliers are reassessing sourcing strategies, with some accelerating near-shoring initiatives or diversifying supplier portfolios to mitigate single-source risks.

Procurement teams within hospitals, clinics, and pharmacy chains are adapting purchasing practices to manage variability in input costs, which may influence formulary decisions and contract negotiations. At the same time, wholesalers and third-party logistics providers are revising pass-through pricing mechanisms and inventory policies to maintain service levels despite potential margin compression. Distribution channels that rely on cross-border flows, such as certain online pharmacy models and specialty suppliers, face heightened compliance and cost-management burdens.

Moreover, tariff-driven uncertainty is catalyzing strategic investment in domestic manufacturing capacity and in manufacturing technologies that improve yield and reduce dependence on imported intermediates. Investors and manufacturers are weighing capital allocation toward flexible production platforms that can quickly switch between molecules, thereby improving resilience. For clinicians and health systems, the most immediate implications manifest as a need for proactive supply planning and transparent communication to safeguard continuity of care for patients reliant on chronic antiviral therapy.

Translating molecule, therapy model, distribution, administration route, end-user, and indication segmentation into clear strategic lenses for clinical and commercial decision-makers

A nuanced segmentation framework helps clarify where clinical demand, distribution dynamics, and commercial focus converge, beginning with molecule-level distinctions. The market is analyzed across acyclovir, famciclovir, and valacyclovir, each presented with branded and generic formulations for the more established agents. Those molecule distinctions inform prescribing patterns and pricing strategies, as clinicians weigh pharmacokinetics, adherence profiles, and tolerability when selecting agents for episodic or suppressive regimens.

Therapy model segmentation highlights episodic therapy, prophylactic therapy, and suppressive therapy as distinct care pathways with different clinical intents and resource requirements. Episodic therapy prioritizes acute symptom control, prophylactic therapy targets defined exposure risk windows, and suppressive therapy aims to minimize recurrence and asymptomatic shedding over extended periods. Distribution channel analysis spans hospital pharmacy, online pharmacy, and retail pharmacy, with hospital pharmacies differentiated into private and public facilities, online channels split between manufacturer-direct and third-party e-retailers, and retail outlets split into chain and independent pharmacies. These distribution distinctions affect procurement cycles, reimbursement interactions, and patient access, particularly as online and retail channels expand.

Route-of-administration segmentation recognizes intravenous, oral, and topical options, with intravenous use further categorized into home infusion and hospital administration; oral preparations examined across capsules, liquid, and tablets; and topical agents catalogued as creams and ointments. Route selection influences care setting, monitoring needs, and adherence interventions. End-user classification encompasses homecare settings, hospitals, and specialty clinics, with homecare further divided into nurse-administered and self-administered care, hospitals into private and public institutions, and specialty clinics into dermatology and sexually transmitted disease clinics; these distinctions shape training, reimbursement, and supply logistics. Lastly, indication-based segmentation considers asymptomatic shedding, primary infection, and recurrent episodes, with primary infection subdivided into adult and pediatric presentations and recurrent episodes distinguished between first recurrence and multiple recurrences, each demanding tailored clinical approaches and patient education strategies.

Taken together, this segmentation matrix provides a multi-dimensional lens through which manufacturers, clinicians, distributors, and payers can align product portfolios, service delivery models, and commercial tactics to the clinical realities and access pathways that define patient journeys.

Discerning how regional regulatory frameworks, manufacturing capabilities, distribution channels, and cultural factors differentially shape access and clinical practice across global markets

Regional dynamics shape how therapies are developed, regulated, procured, and delivered, with the Americas, Europe Middle East & Africa, and Asia-Pacific each presenting distinct operational realities. In the Americas, private-sector innovation, telemedicine adoption, and a substantial presence of retail and online pharmacy channels drive rapid uptake of digital-enabled care models, while payer arrangements and formulary management continue to shape prescribing choices and treatment continuity.

The Europe Middle East & Africa region encompasses a wide regulatory and economic spectrum, where centralized regulatory frameworks and nation-level procurement policies influence access in public hospital settings, and where private-sector clinics and specialty providers play pivotal roles in urban centers. Differences in reimbursement and public health priorities require adaptive market strategies and nuanced engagement with national health authorities.

Asia-Pacific is characterized by a robust manufacturing base, significant generic production capacity, and diverse access profiles that range from high-resource metropolitan markets to under-resourced rural areas. Regulatory harmonization efforts and investments in point-of-care diagnostics are accelerating in several markets, while e-commerce channels and private retail networks are expanding access in both urban and peri-urban contexts. Across regions, cultural factors, stigma, and health-seeking behavior further modulate demand for diagnostics and therapy, underscoring the need for region-specific patient engagement and commercialization approaches.

Understanding competitive positioning, partnership strategies, and differentiation levers among manufacturers, distributors, diagnostics providers, and clinical service networks

Competitive dynamics in genital herpes treatment reflect a balance between established small-molecule antivirals, an expanding generic supply base, and emerging clinical- and commercial-service providers. Branded originators have historically established clinical positioning through physician relationships, clinical data, and branded education, while generic manufacturers leverage cost efficiencies and broad distribution to increase access. Contract manufacturers and specialty supply partners play a pivotal role in supporting flexible production schedules and in meeting regulatory quality standards across markets.

Pharmaceutical companies and distributors are increasingly forming partnerships with digital health platforms and e-retailers to streamline prescription fulfillment and to integrate adherence support tools into the patient journey. Diagnostic companies that can provide rapid, reliable molecular testing have become strategic collaborators, enabling targeted prescribing and reinforcing stewardship principles. In parallel, specialty clinics and dermatology networks act as important nodes for diagnosis and management, particularly for complex or recurrent cases that require multidisciplinary care.

Where innovation occurs, it often centers on formulation improvements, long-acting delivery mechanisms, and adjunctive technologies that enhance adherence. Companies that invest in clinician education, patient support programs, and integrated diagnostic-therapeutic pathways are better positioned to influence treatment algorithms and to capture durable clinical relationships. Ultimately, competitive advantage accrues to organizations that can combine clinical credibility, supply resilience, and novel distribution strategies to meet evolving provider and patient expectations.

Actionable strategic imperatives for manufacturers, payers, and providers to strengthen supply resilience, integrate diagnostics, and expand patient-centric access pathways

Industry leaders should pursue a coordinated strategy that integrates supply chain resilience, clinical evidence generation, and patient-centered distribution models. First, prioritize supplier diversification and flexible manufacturing capabilities to reduce exposure to single-source inputs and to accommodate rapid shifts in demand or policy-induced cost pressures. Parallel investments in domestic or regional production capacity can mitigate cross-border tariff and transportation risks while shortening replenishment lead times.

Second, invest in diagnostic integration and digital tools that support targeted prescribing, adherence monitoring, and virtual follow-up. By aligning diagnostics with therapy, stakeholders can improve clinical outcomes and demonstrate real-world value to payers and health systems. Third, expand channel partnerships to include manufacturer-direct online fulfillment, third-party e-retailers, and community pharmacy networks, thereby ensuring multiple access points for patients while preserving clinical oversight and adherence support.

Fourth, engage proactively with payers, health authorities, and clinical guideline committees to communicate evidence on therapeutic effectiveness, adherence impacts, and real-world outcomes. Fifth, design patient support programs that address stigma, provide education, and facilitate adherence across both adult and pediatric populations. Finally, prioritize pipeline investments that address long-acting formulations, improved tolerability, and preventive strategies, while maintaining a disciplined portfolio approach that balances near-term generics-led access with longer-term innovation.

Explaining the integrated mixed-methods research approach that combines clinical literature review, regulatory analysis, stakeholder interviews, and supply chain validation to ensure robust insights

The research underpinning this analysis employs a multi-method approach that synthesizes peer-reviewed clinical literature, regulatory documentation, supply chain intelligence, and stakeholder interviews. Clinical insights derive from an appraisal of recent trials, guideline updates, and practice patterns documented in medical literature, while regulatory and procurement observations are informed by public records and policy analyses. Supply chain and manufacturing dynamics reflect interviews with industry operations leaders and contract manufacturing experts, complemented by secondary literature on trade and tariff implications.

Commercial channel and patient-access insights were validated through consultations with pharmacy leaders, telemedicine providers, and specialty clinic administrators, ensuring that observed trends in online fulfillment and retail distribution are grounded in operational realities. The study also incorporates qualitative input from clinicians across adult and pediatric specialties to contextualize therapy model preferences and adherence considerations. Throughout, findings were cross-checked for internal consistency and triangulated across multiple sources to reduce bias.

Limitations include variability in published literature across geographies and the inherent lag between emerging commercial maneuvers and their full-scale market effects. To address this, the methodology emphasizes primary interviews and contemporaneous industry reporting to capture near-term shifts. Documentation of methods, interview protocols, and validation steps is available for purchasers seeking deeper methodological transparency.

Consolidating the strategic implications of diagnostic progress, distribution evolution, and formulation innovation for durable improvements in genital herpes care

In sum, the clinical and commercial management of genital herpes is being reshaped by diagnostic advances, distribution innovation, and evolving expectations around long-term suppression and prevention. Stakeholders must reconcile the enduring role of established oral antivirals with changing access pathways, a growing generics presence, and renewed interest in formulations and preventive strategies that could alter long-term care models. Supply chain resilience and strategic sourcing have come to the fore in light of policy shifts that influence cost structures and procurement behaviors.

Equally important is the need to operationalize patient-centered approaches that integrate rapid diagnostics, telehealth-enabled follow-up, and adherence support to improve outcomes and reduce transmission risk. Regional nuances will continue to dictate tailored market tactics, and leaders who align manufacturing flexibility, channel diversification, and evidence-driven engagement with payers and clinicians will be best positioned to deliver both clinical value and sustainable commercial performance. Moving forward, a balanced focus on immediate access needs and longer-term innovation priorities will be essential for durable impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Genital Herpes Treatment Market, by Molecule

  • 8.1. Acyclovir
    • 8.1.1. Branded
    • 8.1.2. Generic
  • 8.2. Famciclovir
    • 8.2.1. Branded
    • 8.2.2. Generic
  • 8.3. Valacyclovir
    • 8.3.1. Branded
    • 8.3.2. Generic

9. Genital Herpes Treatment Market, by Therapy Model

  • 9.1. Episodic Therapy
  • 9.2. Prophylactic Therapy
  • 9.3. Suppressive Therapy

10. Genital Herpes Treatment Market, by Route Of Administration

  • 10.1. Intravenous
    • 10.1.1. Home Infusion
    • 10.1.2. Hospital Administration
  • 10.2. Oral
    • 10.2.1. Capsules
    • 10.2.2. Liquid
    • 10.2.3. Tablets
  • 10.3. Topical
    • 10.3.1. Cream
    • 10.3.2. Ointment

11. Genital Herpes Treatment Market, by Indication

  • 11.1. Asymptomatic Shedding
  • 11.2. Primary Infection
    • 11.2.1. Adults
    • 11.2.2. Pediatrics
  • 11.3. Recurrent Episodes
    • 11.3.1. First Recurrence
    • 11.3.2. Multiple Recurrences

12. Genital Herpes Treatment Market, by End User

  • 12.1. Homecare Settings
    • 12.1.1. Nurse-administered
    • 12.1.2. Self-administered
  • 12.2. Hospitals
    • 12.2.1. Private
    • 12.2.2. Public
  • 12.3. Specialty Clinics
    • 12.3.1. Dermatology Clinics
    • 12.3.2. STD Clinics

13. Genital Herpes Treatment Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
    • 13.1.1. Private Hospital Pharmacy
    • 13.1.2. Public Hospital Pharmacy
  • 13.2. Online Pharmacy
    • 13.2.1. Manufacturer Direct
    • 13.2.2. Third Party E-retailer
  • 13.3. Retail Pharmacy
    • 13.3.1. Chain Pharmacy
    • 13.3.2. Independent Pharmacy

14. Genital Herpes Treatment Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Genital Herpes Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Genital Herpes Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Genital Herpes Treatment Market

18. China Genital Herpes Treatment Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Abcam PLC
  • 19.7. Aurobindo Pharma Limited
  • 19.8. Bio-Rad Laboratories, Inc.
  • 19.9. bioMerieux SA
  • 19.10. Cipla Limited
  • 19.11. DiaSorin S.p.A.
  • 19.12. Dr. Reddy's Laboratories Ltd
  • 19.13. F. Hoffmann-La Roche Ltd.
  • 19.14. GlaxoSmithKline plc
  • 19.15. Hikma Pharmaceuticals plc
  • 19.16. Hologic, Inc.
  • 19.17. Luminex Corporation - A DiaSorin Company
  • 19.18. Lupin Limited
  • 19.19. Merck KGaA
  • 19.20. Meridian Bioscience, Inc. by SD Biosensor and SJL Partners
  • 19.21. Norgen Biotek Corporation
  • 19.22. OneCare Media, LLC
  • 19.23. Qiagen N.V.
  • 19.24. Quidel Corporation
  • 19.25. Rapid STD Testing by RSC Health, PA
  • 19.26. Sandoz International GmbH
  • 19.27. Sun Pharmaceutical Industries Ltd
  • 19.28. Teco Diagnostics
  • 19.29. Teva Pharmaceutical Industries Ltd
  • 19.30. Thermo Fisher Scientific, Inc.
  • 19.31. Viatris Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENITAL HERPES TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENITAL HERPES TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY MOLECULE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY THERAPY MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA GENITAL HERPES TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ACYCLOVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ACYCLOVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ACYCLOVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ACYCLOVIR, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY FAMCICLOVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY FAMCICLOVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY FAMCICLOVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY FAMCICLOVIR, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY VALACYCLOVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY VALACYCLOVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY VALACYCLOVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY VALACYCLOVIR, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY EPISODIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY EPISODIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY EPISODIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PROPHYLACTIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PROPHYLACTIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PROPHYLACTIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY SUPPRESSIVE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY SUPPRESSIVE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY SUPPRESSIVE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOME INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOME INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOME INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY OINTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ASYMPTOMATIC SHEDDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ASYMPTOMATIC SHEDDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ASYMPTOMATIC SHEDDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PRIMARY INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PRIMARY INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PRIMARY INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PRIMARY INFECTION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY RECURRENT EPISODES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY RECURRENT EPISODES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY RECURRENT EPISODES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY RECURRENT EPISODES, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY FIRST RECURRENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY FIRST RECURRENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY FIRST RECURRENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY MULTIPLE RECURRENCES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY MULTIPLE RECURRENCES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY MULTIPLE RECURRENCES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY NURSE-ADMINISTERED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY NURSE-ADMINISTERED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY NURSE-ADMINISTERED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY SELF-ADMINISTERED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY SELF-ADMINISTERED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY SELF-ADMINISTERED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY STD CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY STD CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY STD CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY MANUFACTURER DIRECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY MANUFACTURER DIRECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY MANUFACTURER DIRECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY THIRD PARTY E-RETAILER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY THIRD PARTY E-RETAILER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY THIRD PARTY E-RETAILER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY ACYCLOVIR, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY FAMCICLOVIR, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY VALACYCLOVIR, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY PRIMARY INFECTION, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY RECURRENT EPISODES, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY ACYCLOVIR, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY FAMCICLOVIR, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY VALACYCLOVIR, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY PRIMARY INFECTION, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY RECURRENT EPISODES, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY ACYCLOVIR, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY FAMCICLOVIR, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY VALACYCLOVIR, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY PRIMARY INFECTION, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY RECURRENT EPISODES, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA GENITAL HERPES TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ACYCLOVIR, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY FAMCICLOVIR, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY VALACYCLOVIR, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY PRIMARY INFECTION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY RECURRENT EPISODES, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY ACYCLOVIR, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY FAMCICLOVIR, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY VALACYCLOVIR, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY PRIMARY INFECTION, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY RECURRENT EPISODES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE GENITAL HERPES TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY ACYCLOVIR, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY FAMCICLOVIR, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY VALACYCLOVIR, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 280. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY PRIMARY INFECTION, 2018-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY RECURRENT EPISODES, 2018-2032 (USD MILLION)
  • TABLE 282. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 284. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 286. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 288. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST GENITAL HERPES TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ACYCLOVIR, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY FAMCICLOVIR, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY VALACYCLOVIR, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 296. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 300. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 301. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY PRIMARY INFECTION, 2018-2032 (USD MILLION)
  • TABLE 302. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY RECURRENT EPISODES, 2018-2032 (USD MILLION)
  • TABLE 303. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 305. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 306. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 307. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 309. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 310. AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY